Vanda Pharmaceuticals
VNDA
179 hedge funds and large institutions have $227M invested in Vanda Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 65 reducing their positions, and 35 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 65
5% less funds holding
Funds holding: 188 → 179 (-9)
6.96% less ownership
Funds ownership: 97.93% → 90.97% (-7%)
20% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 35
39% less capital invested
Capital invested by funds: $371M → $227M (-$144M)
58% less call options, than puts
Call options by funds: $35K | Put options by funds: $83K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.98M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.56M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.7M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.4M |
| 5 |
Morgan Stanley
New York
|
+$3.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$22.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.4M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$8.27M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.23M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.44M |
VNDA Hedge Fund Activity: Q3 2023 in Review
179 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2023, worth a combined $227M — down 39% from $371M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of VNDA and 28 opened new positions — a net loss of 7 holders — while 65 trimmed existing stakes and 64 added.
The largest buyer was Millennium Management, adding an estimated $7.98M. The largest seller was BlackRock, cutting an estimated $22.5M.
- 179 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2023, down from 188 in Q2 2023.
- Funds reported $227M of Vanda Pharmaceuticals stock for Q3 2023, down 39% quarter-over-quarter.
- 28 funds opened new Vanda Pharmaceuticals positions in Q3 2023 and 35 closed out, a net change of -7 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $7.98M added.
- The largest Vanda Pharmaceuticals seller in Q3 2023 was BlackRock, an estimated $22.5M sold.
Based on aggregated 13F filings for Q3 2023.